SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
The company resolved its continued listing deficiencies under Section 1003 to end a compliance investigation. This reinstates full status with NYSE American and removes the technic…
Trilogy Metals announced a coordinated permitting schedule for the Arctic Project with a targeted Record of Decision in September 2028. This milestone sets a synchronized roadmap f…
The FDA has issued an Emergency Use Authorization for Ivermectin Liquid for Horses to prevent New World Screwworm infestations during the first 24 hours of life or upon initial wou…
Visa Inc. filed an exhibit further amending its corporate bylaws to allow meetings to be held remotely and to clarify notice requirements for stockholders.
BBCMS Mortgage Trust 2023-5C23 filed a Form 8-K with the SEC on July 15, 2026. The provided text contains only filing header information and lacks details regarding the specific bu…
The company submitted a current report with the SEC on July 15, 2026, outlining material events and updates.
NeOnc Technologies received detailed FDA feedback regarding the Chemistry, Manufacturing and Controls for its NEO212 candidate, including actionable steps for a tablet formulation …
The company submitted an 8-K exhibit to the SEC, which appears to be a standard form with no immediate material business impact or financial data disclosed.
Veradermics announced positive Phase 2 study results for VDPHL01 in female hair loss. The data positions the drug as a potential first FDA-approved oral treatment for this indicati…
Axsome Therapeutics announced the FDA accepted its NDA for AXS-12 to treat cataplexy in narcolepsy, setting a PDUFA target date of May 1, 2027. This regulatory milestone advances t…
Green Thumb Industries Inc. filed an amended and restated certificate of incorporation to update its governance framework. This routine regulatory filing indicates no material chan…
The Federal Board of Governors released minutes from its June 8 and June 17, 2026, discount rate meetings, detailing policy discussions.
Celcuity announced FDA approval for the REVTORPYK targeted therapy to treat HR+/HER2- breast cancer without a PIK3CA mutation. The drug reduced the risk of disease progression or d…
Atrium Therapeutics obtained FDA clearance to launch the Phase 1/2 Corventis trial for the precision cardiology candidate ATR 1072. This regulatory milestone validates the company'…
SBC Medical Group filed an amended and restated certificate of incorporation to update its corporate name and authorized capital structure. This regulatory update defines the issua…
UBS Commercial Mortgage Securitization Corp. filed a Form 8-K with the SEC on July 14, 2026, regarding UBS Commercial Mortgage Trust 2018-C14. The filing confirms the registrant an…
The company filed an amended and restated certificate of incorporation to update governance structures. This regulatory filing outlines new powers for the board of directors.
CervoMed released new analyses from its Phase 2b trial reinforcing neflamapimod's efficacy. The data supports selecting the 50 mg dose for Phase 3, enhancing investor confidence in…
Ausenco Engineering Canada ULC consented to the use of its technical report sections regarding the Grassy Mountain Project in the company's official filings. This document serves a…
D-Wave Quantum has voluntarily transferred its common stock listing from the New York Stock Exchange to Nasdaq. The stock will continue trading under the QBTS ticker symbol.